AR055667A1 - Compuestos de (piran-piperidinil)becimidazol, composicion farmaceutica que lo comprende, su uso para preparar un medicamento para el tratamiento de trastornos mediados por el agonismo del receptor m1, procesos para prepararlo y compuestos de utilidad como intermediarios de la sintesis de los mismos. - Google Patents
Compuestos de (piran-piperidinil)becimidazol, composicion farmaceutica que lo comprende, su uso para preparar un medicamento para el tratamiento de trastornos mediados por el agonismo del receptor m1, procesos para prepararlo y compuestos de utilidad como intermediarios de la sintesis de los mismos.Info
- Publication number
- AR055667A1 AR055667A1 ARP060104267A ARP060104267A AR055667A1 AR 055667 A1 AR055667 A1 AR 055667A1 AR P060104267 A ARP060104267 A AR P060104267A AR P060104267 A ARP060104267 A AR P060104267A AR 055667 A1 AR055667 A1 AR 055667A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- compound
- formula
- alkyl
- convertible
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 27
- 238000000034 method Methods 0.000 title abstract 12
- 230000008484 agonism Effects 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 11
- 150000003839 salts Chemical class 0.000 abstract 9
- 239000012453 solvate Substances 0.000 abstract 9
- 230000008878 coupling Effects 0.000 abstract 4
- 238000010168 coupling process Methods 0.000 abstract 4
- 238000005859 coupling reaction Methods 0.000 abstract 4
- 125000001153 fluoro group Chemical group F* 0.000 abstract 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 238000010438 heat treatment Methods 0.000 abstract 2
- 239000012442 inert solvent Substances 0.000 abstract 2
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 abstract 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 abstract 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 abstract 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 abstract 1
- 238000003747 Grignard reaction Methods 0.000 abstract 1
- 239000007818 Grignard reagent Substances 0.000 abstract 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- -1 alkyl Grignard reagent Chemical class 0.000 abstract 1
- 230000029936 alkylation Effects 0.000 abstract 1
- 238000005804 alkylation reaction Methods 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 239000003054 catalyst Substances 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000010949 copper Substances 0.000 abstract 1
- 229910052802 copper Inorganic materials 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229910052763 palladium Inorganic materials 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- 238000006722 reduction reaction Methods 0.000 abstract 1
- 238000005932 reductive alkylation reaction Methods 0.000 abstract 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 abstract 1
- 239000008096 xylene Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0519949.2A GB0519949D0 (en) | 2005-09-30 | 2005-09-30 | Compounds |
| GB0602856A GB0602856D0 (en) | 2006-02-13 | 2006-02-13 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR055667A1 true AR055667A1 (es) | 2007-08-29 |
Family
ID=37635729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104267A AR055667A1 (es) | 2005-09-30 | 2006-09-28 | Compuestos de (piran-piperidinil)becimidazol, composicion farmaceutica que lo comprende, su uso para preparar un medicamento para el tratamiento de trastornos mediados por el agonismo del receptor m1, procesos para prepararlo y compuestos de utilidad como intermediarios de la sintesis de los mismos. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8288412B2 (https=) |
| EP (1) | EP1960389B1 (https=) |
| JP (1) | JP5209481B2 (https=) |
| AR (1) | AR055667A1 (https=) |
| ES (1) | ES2391107T3 (https=) |
| PE (1) | PE20070586A1 (https=) |
| TW (1) | TW200804355A (https=) |
| WO (1) | WO2007036718A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0616609A2 (pt) * | 2005-09-30 | 2011-06-28 | Glaxo Group Ltd | compostos que têm atividade no receptor m1, composição farmacêutica contendo tais compostos, processo para preparação dos mesmos, bem como seus usos em medicina |
| WO2007036711A1 (en) * | 2005-09-30 | 2007-04-05 | Glaxo Group Limited | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR |
| EP1960389B1 (en) | 2005-09-30 | 2012-08-15 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
| GB0605784D0 (en) * | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
| GB0706165D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706170D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706164D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706174D0 (en) * | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0718415D0 (en) * | 2007-09-20 | 2007-10-31 | Glaxo Group Ltd | Compounds |
| UY31672A1 (es) * | 2008-02-28 | 2009-09-30 | "agonistas de receptores muscarínicos composiciones farmacéuticas métodos de tratamiento de los mismos, y procedimientos para su preparación" | |
| US20090221642A1 (en) * | 2008-03-03 | 2009-09-03 | Astrazeneca Ab | Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof-176 |
| GB0817982D0 (en) | 2008-10-01 | 2008-11-05 | Glaxo Group Ltd | Compounds |
| WO2010103306A1 (en) | 2009-03-10 | 2010-09-16 | Astrazeneca Uk Limited | Benzimidazole derivatives and their use as antivaral agents |
| US20180250270A1 (en) | 2015-09-11 | 2018-09-06 | Chase Pharmaceuticals Corporation | Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system |
| CN106316864A (zh) * | 2016-08-22 | 2017-01-11 | 苏州天马精细化学品股份有限公司 | 4‑甲基‑3‑三氟甲基苯胺的制备方法 |
| CN111848406B (zh) * | 2019-04-26 | 2022-03-29 | 沈阳中化农药化工研发有限公司 | 一种2-氯-4-氟-5-硝基苯甲醛的制备方法 |
| CN113637001A (zh) * | 2021-08-09 | 2021-11-12 | 安康市农业科学研究院 | 一种氟哌利多中间体的合成方法 |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3161645A (en) | 1962-12-18 | 1964-12-15 | Res Lab Dr C Janssen N V | 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds |
| US3989707A (en) * | 1974-06-21 | 1976-11-02 | Janssen Pharmaceutica N.V. | Benzimidazolinone derivatives |
| US4292321A (en) | 1979-05-24 | 1981-09-29 | Warner-Lambert Company | 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof |
| US4411904A (en) * | 1981-05-29 | 1983-10-25 | Warner-Lambert Company | Diphenylpropanamines, compositions thereof and use thereof |
| DE3124366A1 (de) | 1981-06-20 | 1982-12-30 | Hoechst Ag, 6000 Frankfurt | N-oxacyclyl-alkylpiperidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und deren verwendung |
| DE4040300A1 (de) | 1990-12-17 | 1992-07-02 | Leifeld Gmbh & Co | Drueckmaschine mit wenigstens einem rollenhalter |
| JP3916093B2 (ja) * | 1993-09-17 | 2007-05-16 | 杏林製薬株式会社 | 光学活性イミダゾリジノン誘導体とその製造方法 |
| JP2002515008A (ja) * | 1994-10-27 | 2002-05-21 | メルク エンド カンパニー インコーポレーテッド | ムスカリン・アンタゴニスト |
| US5691323A (en) * | 1995-05-12 | 1997-11-25 | Merck & Co., Inc. | Muscarine antagonists |
| US5574044A (en) | 1994-10-27 | 1996-11-12 | Merck & Co., Inc. | Muscarine antagonists |
| WO1997016186A1 (en) | 1995-10-31 | 1997-05-09 | Merck & Co., Inc. | Muscarine agonists |
| US5718912A (en) | 1996-10-28 | 1998-02-17 | Merck & Co., Inc. | Muscarine agonists |
| US5977134A (en) | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6465484B1 (en) | 1997-09-26 | 2002-10-15 | Merck & Co., Inc. | Angiogenesis inhibitors |
| US6162804A (en) | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| AU2307999A (en) | 1997-12-23 | 1999-07-12 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| ATE275141T1 (de) * | 1999-10-13 | 2004-09-15 | Banyu Pharma Co Ltd | Substituierte imidazolin-derivate |
| SE9904652D0 (sv) | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
| US20020019395A1 (en) | 2000-02-01 | 2002-02-14 | Bing-Yan Zhu | Indalone and benzimidazolone inhibitors of factor Xa |
| US6872733B2 (en) | 2001-04-18 | 2005-03-29 | Euro-Celtique S.A. | Benzimidazolone compounds |
| JPWO2002085890A1 (ja) | 2001-04-20 | 2004-08-12 | 萬有製薬株式会社 | ベンズイミダゾロン誘導体 |
| US6951849B2 (en) | 2001-10-02 | 2005-10-04 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| ATE516030T1 (de) | 2001-10-02 | 2011-07-15 | Acadia Pharm Inc | Benzimidazolidinon-derivate als muscarinische mittel |
| WO2004089942A2 (en) | 2001-10-02 | 2004-10-21 | Acadia Pharmaceuticals Inc. | Benzimidazolidinone derivatives as muscarinic agents |
| WO2003037890A2 (en) | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Piperidines |
| JP4056977B2 (ja) | 2002-03-29 | 2008-03-05 | 田辺三菱製薬株式会社 | 睡眠障害治療薬 |
| JP2005532361A (ja) | 2002-06-17 | 2005-10-27 | メルク エンド カムパニー インコーポレーテッド | 高眼圧症の治療用の眼科用組成物 |
| BR0317230A (pt) | 2002-12-13 | 2005-10-25 | Smithkline Beecham Corp | Composto, composição, métodos de antagonizar uma atividade do receptor de quimiocina ccr-5, e de tratar uma infecção viral em um paciente, e, uso de um composto |
| WO2005009996A1 (en) | 2003-07-23 | 2005-02-03 | Wyeth | Sulfonyldihydro- benzimidazolone compounds as 5-hydroxytryptamine-6 ligands |
| KR100738784B1 (ko) | 2003-09-03 | 2007-07-12 | 화이자 인코포레이티드 | 5-ｈｔ4 수용체 효능 활성을 갖는 벤즈이미다졸론 |
| MX2007005290A (es) | 2004-11-02 | 2007-07-09 | Pfizer | Derivados de sulfonilbencimidazol. |
| US7300947B2 (en) | 2005-07-13 | 2007-11-27 | Banyu Pharmaceutical Co., Ltd. | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
| EP1960389B1 (en) | 2005-09-30 | 2012-08-15 | Glaxo Group Limited | Compounds which have activity at m1 receptor and their uses in medicine |
| BRPI0616609A2 (pt) | 2005-09-30 | 2011-06-28 | Glaxo Group Ltd | compostos que têm atividade no receptor m1, composição farmacêutica contendo tais compostos, processo para preparação dos mesmos, bem como seus usos em medicina |
| WO2007036711A1 (en) | 2005-09-30 | 2007-04-05 | Glaxo Group Limited | BENZIMIDAZOLONES WHICH HAVE ACTIVITY AT Ml RECEPTOR |
| WO2008029377A2 (en) | 2006-09-08 | 2008-03-13 | The Gillette Company | Toothbrush with multiple bristle states |
| GB0706170D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706173D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706190D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706187D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706167D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706189D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706164D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706165D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706188D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706174D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
| GB0706168D0 (en) | 2007-03-29 | 2007-05-09 | Glaxo Group Ltd | Compounds |
-
2006
- 2006-09-27 EP EP06794587A patent/EP1960389B1/en active Active
- 2006-09-27 WO PCT/GB2006/003595 patent/WO2007036718A2/en not_active Ceased
- 2006-09-27 US US12/088,451 patent/US8288412B2/en not_active Expired - Fee Related
- 2006-09-27 ES ES06794587T patent/ES2391107T3/es active Active
- 2006-09-27 JP JP2008532868A patent/JP5209481B2/ja not_active Expired - Fee Related
- 2006-09-28 PE PE2006001184A patent/PE20070586A1/es not_active Application Discontinuation
- 2006-09-28 AR ARP060104267A patent/AR055667A1/es not_active Application Discontinuation
- 2006-09-28 TW TW095135888A patent/TW200804355A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1960389A2 (en) | 2008-08-27 |
| US8288412B2 (en) | 2012-10-16 |
| PE20070586A1 (es) | 2007-06-16 |
| ES2391107T3 (es) | 2012-11-21 |
| JP5209481B2 (ja) | 2013-06-12 |
| TW200804355A (en) | 2008-01-16 |
| EP1960389B1 (en) | 2012-08-15 |
| WO2007036718A2 (en) | 2007-04-05 |
| JP2009510041A (ja) | 2009-03-12 |
| WO2007036718A3 (en) | 2007-05-31 |
| US20080293770A1 (en) | 2008-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR055667A1 (es) | Compuestos de (piran-piperidinil)becimidazol, composicion farmaceutica que lo comprende, su uso para preparar un medicamento para el tratamiento de trastornos mediados por el agonismo del receptor m1, procesos para prepararlo y compuestos de utilidad como intermediarios de la sintesis de los mismos. | |
| PE20090893A1 (es) | Derivados de pirazol como antagonistas del receptor ccr2 y/o ccr5 | |
| AR066562A1 (es) | Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos | |
| AR060213A1 (es) | Compuesto de piperazinil - piridinil -bencensulfonamida , su uso para fabricar un medicamento proceso para la preparacion del mismo composicion farmaceutica que lo comprende y proceso para prepararla | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| AR061726A1 (es) | Piperidinas sustituidas que aumentan la actividad de p53 y su uso | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| AR042668A1 (es) | Derivados de fosfonoxi quinazolinas y su uso farmaceutico | |
| AR056979A1 (es) | Derivados de dihidrobenzofuranos y usos de los mismos | |
| PE20020720A1 (es) | Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa | |
| PE20161476A1 (es) | Derivados de indolin-2-ona o pirrolo-piridin-2-ona | |
| CA2624504A1 (en) | Benzimidazolone compounds which have activity at m1 receptor and their uses in medicine | |
| AR064831A1 (es) | Derivados de espiropiperidina-glicinamida | |
| BR0307477A (pt) | Compostos quìmicos | |
| PE20080889A1 (es) | Aminometil-4-imidazoles | |
| CY1108880T1 (el) | Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα | |
| PE20160241A1 (es) | Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| CL2007002899A1 (es) | Compuestos derivados de azaciclilaminas n-sustituidas, inhibidores del receptor de histamina 3; proceso de preparacion; composicion farmaceutica que comprende los compuestos, y usopara el tratamiento de trastornos cognitivos, esquizofre nia y enfermedad de alzheimer entre otros. | |
| JP2009512635A5 (https=) | ||
| PE20081446A1 (es) | Quinolinas | |
| ECSP109958A (es) | Derivados de pirimidina 934 | |
| ECSP034898A (es) | 2,5-DIARILPIRAZINAS, 2,5-DIARILPIRIDINAS y 2,5- DIARILPIRIMIDINAS | |
| AR045999A1 (es) | Compuesto de eter de piperidina, su uso para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para prepararlo | |
| AR056888A1 (es) | Derivados de heterociclil imidazol | |
| JP2009510041A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |